Simplified Tranexamic Acid Regimen for Trauma with Hemorrhage
Official title: Simplified Versus Divided-Dose Tranexamic Acid Regimen in Patients With Traumatic Hemorrhagic Shock: A Multicenter, Randomized, Open-Label Pilot Study
Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT07869537 · Data updated 2026-11-12
This trial tests a simplified TXA dosing approach to see if it safely helps adults with major trauma and significant bleeding.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine Academic / other |
| Locations | 3 sites (Hangzhou, Zhejiang and 2 other locations) |
| Status | Recruiting |
| Started | October 1, 2026 |
| Main results expected | March 31, 2027 |
| Study ends | April 30, 2027 |
| Registry record updated | October 9, 2026 |
| Trial ID | NCT07869537 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with trauma and significant hemorrhage treated within 3 hours of injury who consent or meet emergency consent requirements.
✕Probably not a fit
Patients with contraindications to TXA, traumatic arrest on admission, high imminent death risk, or thrombotic history may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, interventional study evaluates a simplified tranexamic acid regimen in adult trauma patients with significant hemorrhage. The goal is to determine whether a streamlined TXA dosing protocol provides safe and effective hemostasis within the critical early hours after injury. Participants must be treated within 3 hours of injury and meet predefined criteria for severe bleeding or high risk of massive transfusion. Exclusion criteria include allergy to TXA, pregnancy, prior traumatic arrest with high short-term mortality risk, thrombotic history, epilepsy, unknown injury time, or prior TXA administration before admission. The study is led by the Second Affiliated Hospital, Zhejiang University School of Medicine, with several regional collaborators in Zhejiang Province, China.
Why it matters
Potential benefit: If successful, patients could experience improved control of bleeding with a potentially simpler TXA regimen.
How similar studies have gone: TXA has shown mortality reduction in traumatic bleeding in prior trials, supporting continued evaluation in simplified regimens.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Trauma patients * Significant hemorrhage (systolic blood pressure \<90 mm Hg or heart rate \>110 beats per min, or both) or clinical assessment of risk of massive transfusion (massive transfusion was defined as administration of at least 3 PRBC within the hour of admission or at least 10 PRBC within the first 24 hours) * who were within 3 h of injury * To obtain informed consent (or comply with the requirements for emergency exemptions agree) Exclusion Criteria: * Known to be allergic to TXA * Pregnancy * Traumatic cardiac arrest occurring prior to or at the time of admission, or patients with a high risk of death within 3 hours of admission * History of thrombotic disease (such as DVT and PE, MI, stroke) * History of epilepsy * Injury time is unknown or \> 3 hours * have received TXA before admission.
Where it's running
-
the Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China Recruiting -
Jiaxing First Hospital
Jiaxin, Zhejiang, China Recruiting -
Third Affiliated Hospital, Wenzhou Medical University
Wenzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: yongan xu
- Email: xuyongan2000@zju.edu.cn
- Phone: 0571-87998893
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Bleeding control after single-ray amputation: Hemocoll vs Avitene vs bone wax
This trial tests whether Hemocoll, Avitene, or bone wax better stop bleeding from exposed bone after a planned single-ray amputation in adults.
-
Stability of blood clotting products in ambulances under real-world conditions
This study checks whether fibrinogen concentrates and Octaplas plasma stay stable when stored in real EMS ambulances in Graz, Austria.
-
Tailored lower‑intensity blood thinner plan after left atrial appendage closure to prevent stroke
This project tests whether people with non‑valvular atrial fibrillation who get a left atrial appendage closure can stop blood thinners after taking low‑dose apixaban (2.5 mg twice daily) for 3 months, compared with people who stay on standard‑dose DOACs.
-
Catheter ablation plus LAAC vs anticoagulation in frail elderly A-fib patients
This study tests whether adding left atrial appendage closure to ablation is as good as using long-term blood thinners in frail people aged 75 and up with atrial fibrillation.
-
Preventing pneumonia after brain hemorrhage with extra mouth care and preventive antibiotics
This will test whether enhanced oral hygiene combined with preventive antibiotics can help adults who recently had a spontaneous intracerebral hemorrhage avoid pneumonia.
-
Comparing tranexamic acid dosing during heart surgery with cardiopulmonary bypass
This research will test whether three different tranexamic acid dosing schedules keep fibrinolysis suppressed longer and limit bleeding in adults having elective heart surgery with cardiopulmonary bypass.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.